Chris is the President of Janssen, the pharmaceutical companies of Johnson & Johnson, in Japan and a member of the Janssen Asia Pacific Leadership Team. He is also Vice Chair of PhRMA Japan and a Board Member of EFPIA Japan.
Since assuming leadership of Janssen Japan in early 2016, Chris has led a strategy to improve the company’s market competitiveness, widening access to innovative medicine, and attracting and retaining the strongest talent in the Japanese market.
Today, Janssen Japan is one of the fastest growing multinational pharmaceutical companies in the country and the second largest Janssen business globally. The company’s investment in its people and work culture was recently recognised when Nikkei Woman ranked the J&J family of companies as No. 1 for Gender Diversity in Japan.
Before moving to Japan, Chris was Managing Director for Janssen Australia & New Zealand (ANZ), where he oversaw significant growth and played a key role in supporting the local industry as a member of the Medicines Australia Board. Chris also initiated the development of a Johnson & Johnson signature program for disadvantaged indigenous populations.
Before leading Janssen ANZ, Chris was Managing Director of Janssen Vietnam, where he developed a long-term strategy to drive transformational growth in this key emerging market. Before this role, Chris was Country Manager for Janssen New Zealand and a Board Member of the industry association, Medicines New Zealand, as well as a member of the Janssen ANZ Leadership Team.
Chris holds a Masters of Business Administration and a Bachelor of Applied Science.
Articles: Chris Hourigan
Japan / Japan’s Opportunity to Establish a Blueprint for the World: Janssen Japan’s Chris Hourigan makes the case for increased investment in, and access to, innovative medicines as a key solution to countering the costs associated with an ageing population. Earlier this year, Emperor Naruhito ascended the Chrysanthemum Throne, and Japan entered a new era, known…